canakinumab
novartis
['nsclc', 'canakinumab', 'canopy-a', 'sclc']
not surprised that canopy-a is negative: teached us that il-1beta fuels the growth of cancer. canakinumab (anti il-1beta) should reduce incidence of second nsclc rather than prevent relapse of the resected one. incidence of 2nd cancer was not presented! #esmo22 
Medical Oncologist - Lung cancer & thymic tumors. Head of Clinical Research @GustaveRoussy - Head of Scientific Chairs Council @EORTC. Tweets are my own.